ARCHIMED Acquires 75% Stake in ActiGraph
May 18, 2020
ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.
- Buyers
- ARCHIMED (ArchiMed)
- Targets
- ActiGraph
- Sellers
- Historic shareholders (including management)
- Industry
- Medical Devices
- Location
- Florida, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.